Cognito

Cognito Expands Communications Partnership With Foxon Media, the Organizer of The Summit for Asset Management (TSAM) Conferences

Retrieved on: 
Wednesday, March 20, 2024
Marketing, Communications, Public Relations, Investor Relations, Cognito, Voco Orchard Singapore, Northern Trust, Partnership, ESG, Social media, Asset management, Eastspring Investments, Summit, Investment, State Street

Foxon Media , a leading organizer of financial services events, is expanding its partnership with Cognito, the independent global communications agency focused on financial markets, technology, and the climate transition.

Key Points: 
  • Foxon Media , a leading organizer of financial services events, is expanding its partnership with Cognito, the independent global communications agency focused on financial markets, technology, and the climate transition.
  • Cognito will provide media, press functions and social media support for Foxon Media's The Summit for Asset Management (TSAM) portfolio, including TSAM Asia; Singapore , TSAM New York , TSAM London ; The Summit for ESG (TSESG) events in New York and London; and The Summit for Wealth Management in London.
  • The Foxon Media-Cognito partnership, which commenced in 2023, focused on the TSAM and TSESG events in New York and London.
  • Andrew Kerry, Managing Director of Foxon Media, said: “Our global collaboration with Cognito continues in 2024.

Cognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Neurology, Medical Devices, Health, Clinical Trials, Cognito, AAN, Disease, American Academy, Therapy, CO, OLE, Annual general meeting, Pharmaceutical industry

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension (OLE) study of Spectris™, a potential disease modifying therapy for the treatment of Alzheimer’s Disease, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, 2024, in Denver, CO.

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension (OLE) study of Spectris™, a potential disease modifying therapy for the treatment of Alzheimer’s Disease, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, 2024, in Denver, CO.
  • The OLE study was a separate 12-month protocol that followed the six-month OVERTURE randomized clinical trial, in which 83% of OVERTURE study participants enrolled.
  • The OLE enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.
  • For more information about the AAN abstract, visit https://www.aan.com/msa/Public/Events/AbstractDetails/55258 .

Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease

Retrieved on: 
Monday, March 11, 2024
Software, Research, Hardware, Pharmaceutical, Data Management, Technology, Medical Devices, Clinical Trials, Science, Neurology, Biotechnology, Health, Other Science, Cognito, Conference, MRI, HOPE, Parkinson's disease, Disease, Patient, Amyloid-related imaging abnormalities, OLE, ARIA, Clinical trial, Therapy, Safety, WBV, Pharmaceutical industry

The results support for Spectris’™ potential as a disease modifying therapy that, if approved, could also be used as an early intervention for the treatment of Alzheimer’s Disease (AD).

Key Points: 
  • The results support for Spectris’™ potential as a disease modifying therapy that, if approved, could also be used as an early intervention for the treatment of Alzheimer’s Disease (AD).
  • These results provide support for the potential safety of prolonged treatment and highlight the potential for Spectris as a potential disease modifying therapy to preserve both brain structure and function in patients with AD,” said Brent Vaughan, CEO of Cognito Therapeutics.
  • 83% of the OVERTURE study patients (44/53) entered a separate 12-month open label extension (OLE) study, which allowed for further evaluation of Spectris’ potential as a disease modifying therapy.
  • “These results are consistent with accepted criteria for disease modification and support potential for use as early treatment of AD.

Cognito Therapeutics Announces Oral Presentation on Spectris Therapy Open-Label Study Data in Alzheimer’s Disease at AD/PD 2024

Retrieved on: 
Wednesday, February 28, 2024
Mental Health, Health, Neurology, Genetics, Pharmaceutical, Biotechnology, Cognito, Conference, Safety, Therapy, OLE, Clinical trial, RCT, MRI, Pharmaceutical industry

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present data from an open label extension study evaluating its potential novel therapy, Spectris, in Alzheimer’s Disease (AD), as an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease, held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present data from an open label extension study evaluating its potential novel therapy, Spectris, in Alzheimer’s Disease (AD), as an oral presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease, held March 5-9, 2024 in Lisbon, Portugal.
  • “We are excited to present the results from our open label extension study at AD/PD 2024, showcasing the long-term treatment effect of our potential disease-modifying novel therapy, Spectris, over an 18-month period,” said Brent Vaughan, CEO of Cognito Therapeutics.
  • OLE data was analyzed using a delayed start study design to demonstrate evidence of Spectris’ potential disease modifying (DM) therapy.
  • Participants who completed the six-month RCT were eligible to receive 1-hour daily treatment for an additional 12 months in the OLE.

Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology

Retrieved on: 
Wednesday, March 6, 2024
Technology, Medical Devices, General Health, Neurology, Science, Consumer, Clinical Trials, Biotechnology, Health, Health Technology, Other Science, Research, Software, Hardware, Pharmaceutical, Data Management, Seniors, Cognito, Caregiver, Amyloid-related imaging abnormalities, Aes, HOPE, Alzheimer's disease, Political moderate, ARIA, Safety, Hope, Therapy, Memory, EEG, Tolerability, Patient, Clinical trial, Atrophy, MRI, Medical imaging

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today the publication of the OVERTURE study results in Frontiers in Neurology .
  • The OVERTURE clinical trial was a randomized, double-blind, sham-controlled clinical trial conducted over a six-month period at 5 US clinical trial sites, involving participants with mild to moderate AD.
  • Participants were randomly assigned 2:1 to receive self-administered daily, one-hour Spectris therapy designed to evoke EEG-verified gamma oscillations or sham treatment.
  • “Publication of OVERTURE clinical trial results is an important step in our commitment to develop our technology-based therapeutic intervention in Alzheimer’s disease,” said Ralph Kern, M.D., MHSc, Chief Medical Officer of Cognito Therapeutics.

Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease

Retrieved on: 
Monday, December 11, 2023
Technology, Medical Devices, Neurology, Science, Consumer, Clinical Trials, Biotechnology, Health, Other Science, Research, Other Technology, Software, Other Health, Hardware, Pharmaceutical, Data Management, Seniors, Axon, Therapy, Alzheimer's disease, HOPE, White, Hippocampus, Disease, Clinical trial, Journal of Alzheimer's Disease, Learning, White matter, Patient, Journal, FDA, Atrophy, Memory, MRI, Cognito, HIV disease progression rates, Medical imaging

Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .

Key Points: 
  • Cognito Therapeutics , a neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, announced today publication of MRI imaging data from its Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease .
  • White matter volume assessments were performed using T1-weighted MRI, and myelin content assessments were performed using T1-weighted/T2-weighted MRI ratios.
  • “Our Phase 2 OVERTURE study imaging results published in the Journal of Alzheimer's Disease, show that our proprietary gamma sensory stimulation reduced white matter atrophy and preserved brain myelin content in patients.
  • The Company’s lead therapy is currently in a pivotal study (HOPE) in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation.

Cognito Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Neurology, Health, Clinical Trials, Health Technology, CNS, EST, Cognito, Conference, Burns, Therapy

Cognito Therapeutics , a late-stage neuroscience company developing disease-modifying therapies to treat CNS diseases, today announced that Brent Vaughan, Chief Executive Officer, will present at the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023 in New York, NY.

Key Points: 
  • Cognito Therapeutics , a late-stage neuroscience company developing disease-modifying therapies to treat CNS diseases, today announced that Brent Vaughan, Chief Executive Officer, will present at the 35th Annual Piper Sandler Healthcare Conference, being held November 28-30, 2023 in New York, NY.
  • The presentation is scheduled for Wednesday, November 29, 2023 at 2:30 p.m. EST.
  • The Company’s management team will participate in one-on-one investor meetings.
  • To request a meeting, please contact your Piper Sandler representative or Lee Roth of Burns McClellan at [email protected] .

Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer

Retrieved on: 
Monday, October 30, 2023
Technology, Biotechnology, Health, Neurology, Consumer, Pharmaceutical, Research, Medical Devices, Software, Hardware, Science, Seniors, Data Management, Clinical Trials, Lopez v. River Oaks Imaging & Diagnostic Group, Inc., CCO, CNS, Howell, Cognito, Multimedia, Partnership, United States Department of the Navy, Therapy, Alzheimer's disease, Patient, Medtronic, Bachelor of Science in Human Biology, Tulane University, Nursing

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as Chief Commercial Officer (CCO).

Key Points: 
  • Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the appointment of Christian Howell as Chief Commercial Officer (CCO).
  • View the full release here: https://www.businesswire.com/news/home/20231030288290/en/
    “Christian is an accomplished leader with a strong track record building commercial teams and driving global commercial launches in the medical device industry,” said Brent Vaughan, Chief Executive Officer at Cognito Therapeutics.
  • Howell is a former Officer in the United States Navy and holds a Bachelor of Science degree from Tulane University.
  • "I'm excited to be joining Cognito and for the opportunity to support its mission to advance disease-modifying therapies for patients with neurodegenerative diseases," said Christian Howell, Chief Commercial Officer for Cognito Therapeutics.

Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, Șaeș, Headache, Ageing, Neuron, MRI, Incidence, Alzheimer's disease, Atrophy, Amyloid-related imaging abnormalities, ARIA, MD, Safety, Disease, Doctor of Philosophy, HIV disease progression rates, RCT, Cognito, Observation, OLE, Tinnitus, DMT, WBV, Therapy, Randomized controlled trial, Hook effect, Death, Cognition, Pharmaceutical industry, Medical imaging

Continued treatment and switch to active treatment were both well-tolerated with no treatment limiting SAEs or reported ARIA.

Key Points: 
  • Continued treatment and switch to active treatment were both well-tolerated with no treatment limiting SAEs or reported ARIA.
  • The continuous treatment group and the sham-to-active treatment group outcomes did not converge over the 18 month combined study, consistent with disease modification in this patient population.
  • "We are thrilled to share results from our Phase 2 OVERTURE open-label extension study, which reinforces the safety, high adherence, and long-lasting treatment benefits over 18 months of our Disease Modifying Therapy for mild-to-moderate Alzheimer's disease.
  • Clinical stability of function based on total ADCS-ADL was maintained following treatment with active treatment at 18 months.

Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023

Retrieved on: 
Wednesday, October 18, 2023
Technology, Biotechnology, Health, Consumer, Pharmaceutical, Other Science, Research, Medical Devices, Software, Hardware, Science, Seniors, Data Management, Clinical Trials, Atrophy, ARIA, Disease, CNS, HIV disease progression rates, Cognito, White matter, Caregiver, Alzheimer's disease, Neurology, DMT, DSM-IV codes, Safety, Therapy, Patient, Pharmaceutical industry, Paint

Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today it has been selected to present clinical data as a late-breaker abstract from its proprietary investigational disease-modifying therapy in patients with Alzheimer’s Disease, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston and online, October 24-27, 2023.

Key Points: 
  • Cognito Therapeutics , a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today it has been selected to present clinical data as a late-breaker abstract from its proprietary investigational disease-modifying therapy in patients with Alzheimer’s Disease, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston and online, October 24-27, 2023.
  • "We are thrilled to present our Phase 2 study open-label extension results at CTAD 2023, demonstrating that our novel disease modifying therapeutic approach had a durable treatment effect over an 18-month period while uniquely reducing brain atrophy with no treatment limiting significant adverse events or ARIA, in patients with Alzheimer's Disease," said Brent Vaughan, CEO of Cognito Therapeutics.
  • "Our Phase 2 OLE data highlights the safety, high adherence and efficacy of our approach in significantly decelerating disease progression, effectively preserving both brain function and volume in Alzheimer's patients.”
    “We firmly believe that the preservation of brain gray and white matter is an important Alzheimer’s Disease treatment objective and shows a strong correlation with patient outcomes, with far-reaching implications across a variety of neurological disorders,” said Ralph Kern MD MHSc, Chief Medical Officer, Cognito Therapeutics.
  • “Once approved, our DMT can be seamlessly integrated as a home-based treatment into the lives of patients and caregivers, as a novel precision neurology therapy.”
    Details of the poster presentations are below:
    Poster Title: OVERTURE open-label extension data confirm safety, adherence, and durability of treatment benefits over 18 months